• Oncopeptides launched an accelerated bookbuild for a directed share issue of about SEK 100 million to institutional investors.
• Proceeds earmarked for CMC work, trial-start preparations, and funding the next clinical phase in its glioblastoma program.
• HealthCap VIII LP signaled interest to subscribe for SEK 10 million.
• Bookbuild opened Tuesday, ends before trading Wednesday; pricing and share count set with ABG Sundal Collier.
• Cash and cash equivalents totaled SEK 117 million as of Sept. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.